Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review

Detalhes bibliográficos
Autor(a) principal: Bigaran, Larissa Toloy
Data de Publicação: 2022
Outros Autores: Saab, Vivian, Ferreira, Thiago Cabral, Paula, Leandro Bueno de, Barbosa, Talita Costa, Mantelo, Gustavo Moreira, Souza Junior, Sérgio Luiz de, Santos, Pedro Elson Silva dos, Leitao, Gabriela Gil Aguila Saraiva, Maia, Ana Karoline da Silva, Pagliarani, Guilherme Henrique, Fedocci, Elizabete Melo Montanari
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/29361
Resumo: Heart failure (HF) is a complication that may be present in patients with type 2 diabetes mellitus associated with increased risks of morbidity and mortality. HF is common and associated with a poor prognosis, despite advances in treatment. The main biological processes that characterize heart failure with preserved ejection fraction are systemic inflammation, accumulation of epicardial adipose tissue, rarefaction of coronary microcirculation, myocardial fibrosis and vascular stiffness. The resulting impairment of left ventricular and aortic distensibility (especially accompanied by impaired glomerular function and sodium retention) causes increased cardiac filling pressures and exertional dyspnea despite relative preservation of left ventricular ejection fraction. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are one of the classes of glucose-lowering therapies that have demonstrated multi-system health benefits. The three inhibitors that are used are: empaglifozin, canaglifozin and dapagliflozin. Empaglifozin reduced the risk of pump failure and sudden death, the two most common modes in patients with heart failure. Regardless of their actions on blood glucose, SGLT2 inhibitors exert a wide range of biological effects including actions to inhibit cardiac inflammation and fibrosis, antagonize sodium retention, and improve glomerular function that may ameliorate the pathophysiological disorders of heart failure.
id UNIFEI_2cb3f4b9bc47bd537e86aa1890f1aaff
oai_identifier_str oai:ojs.pkp.sfu.ca:article/29361
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature reviewUso de inhibidores del transportador de glucosa sódica 2 en el tratamiento de la insuficiencia cardíaca: una revisión de la literaturaUso dos Inibidores do Transportador 2 de Sódio-Glicose no tratamento da Insuficiência Cardíaca: uma revisão de literatura Inibidores do Transportador 2 de Sódio-GlicoseInsuficiência CardíacaTratamentoEnsino.Inhibidores del cotransportador de sodio-glucosa 2Insuficiencia cardíacaTratamientoEnseñanza. Sodium-glucose transporter 2 inhibitorsHeart failureTreatmentTeaching.Heart failure (HF) is a complication that may be present in patients with type 2 diabetes mellitus associated with increased risks of morbidity and mortality. HF is common and associated with a poor prognosis, despite advances in treatment. The main biological processes that characterize heart failure with preserved ejection fraction are systemic inflammation, accumulation of epicardial adipose tissue, rarefaction of coronary microcirculation, myocardial fibrosis and vascular stiffness. The resulting impairment of left ventricular and aortic distensibility (especially accompanied by impaired glomerular function and sodium retention) causes increased cardiac filling pressures and exertional dyspnea despite relative preservation of left ventricular ejection fraction. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are one of the classes of glucose-lowering therapies that have demonstrated multi-system health benefits. The three inhibitors that are used are: empaglifozin, canaglifozin and dapagliflozin. Empaglifozin reduced the risk of pump failure and sudden death, the two most common modes in patients with heart failure. Regardless of their actions on blood glucose, SGLT2 inhibitors exert a wide range of biological effects including actions to inhibit cardiac inflammation and fibrosis, antagonize sodium retention, and improve glomerular function that may ameliorate the pathophysiological disorders of heart failure.La insuficiencia cardíaca (IC) es una complicación que puede estar presente en pacientes con diabetes mellitus tipo 2 asociada con un aumento de los riesgos de morbilidad y mortalidad. La IC es común y se asocia con un mal pronóstico, a pesar de los avances en el tratamiento. Los principales procesos biológicos que caracterizan la insuficiencia cardíaca con fracción de eyección preservada son la inflamación sistémica, la acumulación de tejido adiposo epicárdico, la rarefacción de la microcirculación coronaria, la fibrosis miocárdica y la rigidez vascular. El deterioro resultante de la distensibilidad del ventrículo izquierdo y la aorta (en especial acompañado de deterioro de la función glomerular y retención de sodio) provoca un aumento de las presiones de llenado cardiaco y disnea de esfuerzo a pesar de la preservación relativa de la fracción de eyección del ventrículo izquierdo. Los inhibidores del cotransportador de sodio-glucosa 2 (SGLT2) son una de las clases de terapias para reducir la glucosa que han demostrado beneficios para la salud multisistémicos. Los tres inhibidores que se utilizan son: empaglifozina, canaglifozina y dapagliflozina. La empaglifozina redujo el riesgo de falla de la bomba y muerte súbita, los dos modos más comunes en pacientes con insuficiencia cardíaca. Independientemente de sus acciones sobre la glucosa en sangre, los inhibidores de SGLT2 ejercen una amplia gama de efectos biológicos que incluyen acciones para inhibir la inflamación y la fibrosis cardíacas, antagonizar la retención de sodio y mejorar la función glomerular que puede mejorar los trastornos fisiopatológicos de la insuficiencia cardíaca.A insuficiência cardíaca (IC) é uma complicação que pode estar presentes nos pacientes acometidos por diabeter mellitus tipo 2 associados a riscos aumentados de morbidade e mortalidade. A IC é comum e associada a mau prognóstico, apesar dos avanços no tratamento. Os principais processos biológicos que caracterizam a insuficiência cardíaca com fração de ejeção preservada são inflamação sistêmica, acúmulo de tecido adiposo epicárdico, rarefação da microcirculação coronariana, fibrose miocárdica e rigidez vascular. O comprometimento resultante da distensibilidade ventricular esquerda e aórtica (especialmente acompanhada de função glomerular prejudicada e retenção de sódio), causa aumento nas pressões de enchimento cardíaco e dispneia de esforço, apesar da preservação relativa da fração de ejeção do ventrículo esquerdo. Os inibidores do cotransportador de sódio-glicose 2 (SGLT2) é uma das classes de terapias de redução de glicose que tem demonstrado benefícios de saúde multissistêmicos. Os três inibidores que são utilizados são: empaglifozina, canaglifozina e dapaglifozina. A empaglifozina reduziu o risco de falência da bomba e morte súbita, os dois modos mais comuns em pacientes com insuficiencia cardíaca. Independentemente de suas ações sobre a glicemia, os inibidores de SGLT2 exercem ampla gama de efeitos biológicos incluindo ações para inibir a inflamação cardíaca e a fibrose, antagonizar a retenção de sódio e melhorar a função glomerular que podem melhorar os distúrbios fisiopatológicos da insuficiência cardíaca.Research, Society and Development2022-05-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2936110.33448/rsd-v11i6.29361Research, Society and Development; Vol. 11 No. 6; e42411629361Research, Society and Development; Vol. 11 Núm. 6; e42411629361Research, Society and Development; v. 11 n. 6; e424116293612525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/29361/25362Copyright (c) 2022 Larissa Toloy Bigaran; Vivian Saab; Thiago Cabral Ferreira; Leandro Bueno de Paula; Talita Costa Barbosa; Gustavo Moreira Mantelo; Sérgio Luiz de Souza Junior; Pedro Elson Silva dos Santos; Gabriela Gil Aguila Saraiva Leitao; Ana Karoline da Silva Maia; Guilherme Henrique Pagliarani; Elizabete Melo Montanari Fedoccihttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBigaran, Larissa Toloy Saab, Vivian Ferreira, Thiago Cabral Paula, Leandro Bueno de Barbosa, Talita Costa Mantelo, Gustavo Moreira Souza Junior, Sérgio Luiz de Santos, Pedro Elson Silva dos Leitao, Gabriela Gil Aguila Saraiva Maia, Ana Karoline da Silva Pagliarani, Guilherme Henrique Fedocci, Elizabete Melo Montanari 2022-05-13T18:04:10Zoai:ojs.pkp.sfu.ca:article/29361Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:46:28.208531Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review
Uso de inhibidores del transportador de glucosa sódica 2 en el tratamiento de la insuficiencia cardíaca: una revisión de la literatura
Uso dos Inibidores do Transportador 2 de Sódio-Glicose no tratamento da Insuficiência Cardíaca: uma revisão de literatura
title Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review
spellingShingle Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review
Bigaran, Larissa Toloy
Inibidores do Transportador 2 de Sódio-Glicose
Insuficiência Cardíaca
Tratamento
Ensino.
Inhibidores del cotransportador de sodio-glucosa 2
Insuficiencia cardíaca
Tratamiento
Enseñanza.
Sodium-glucose transporter 2 inhibitors
Heart failure
Treatment
Teaching.
title_short Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review
title_full Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review
title_fullStr Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review
title_full_unstemmed Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review
title_sort Use of Sodium Glucose Transporter 2 Inhibitors in the treatment of heart failure: a literature review
author Bigaran, Larissa Toloy
author_facet Bigaran, Larissa Toloy
Saab, Vivian
Ferreira, Thiago Cabral
Paula, Leandro Bueno de
Barbosa, Talita Costa
Mantelo, Gustavo Moreira
Souza Junior, Sérgio Luiz de
Santos, Pedro Elson Silva dos
Leitao, Gabriela Gil Aguila Saraiva
Maia, Ana Karoline da Silva
Pagliarani, Guilherme Henrique
Fedocci, Elizabete Melo Montanari
author_role author
author2 Saab, Vivian
Ferreira, Thiago Cabral
Paula, Leandro Bueno de
Barbosa, Talita Costa
Mantelo, Gustavo Moreira
Souza Junior, Sérgio Luiz de
Santos, Pedro Elson Silva dos
Leitao, Gabriela Gil Aguila Saraiva
Maia, Ana Karoline da Silva
Pagliarani, Guilherme Henrique
Fedocci, Elizabete Melo Montanari
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Bigaran, Larissa Toloy
Saab, Vivian
Ferreira, Thiago Cabral
Paula, Leandro Bueno de
Barbosa, Talita Costa
Mantelo, Gustavo Moreira
Souza Junior, Sérgio Luiz de
Santos, Pedro Elson Silva dos
Leitao, Gabriela Gil Aguila Saraiva
Maia, Ana Karoline da Silva
Pagliarani, Guilherme Henrique
Fedocci, Elizabete Melo Montanari
dc.subject.por.fl_str_mv Inibidores do Transportador 2 de Sódio-Glicose
Insuficiência Cardíaca
Tratamento
Ensino.
Inhibidores del cotransportador de sodio-glucosa 2
Insuficiencia cardíaca
Tratamiento
Enseñanza.
Sodium-glucose transporter 2 inhibitors
Heart failure
Treatment
Teaching.
topic Inibidores do Transportador 2 de Sódio-Glicose
Insuficiência Cardíaca
Tratamento
Ensino.
Inhibidores del cotransportador de sodio-glucosa 2
Insuficiencia cardíaca
Tratamiento
Enseñanza.
Sodium-glucose transporter 2 inhibitors
Heart failure
Treatment
Teaching.
description Heart failure (HF) is a complication that may be present in patients with type 2 diabetes mellitus associated with increased risks of morbidity and mortality. HF is common and associated with a poor prognosis, despite advances in treatment. The main biological processes that characterize heart failure with preserved ejection fraction are systemic inflammation, accumulation of epicardial adipose tissue, rarefaction of coronary microcirculation, myocardial fibrosis and vascular stiffness. The resulting impairment of left ventricular and aortic distensibility (especially accompanied by impaired glomerular function and sodium retention) causes increased cardiac filling pressures and exertional dyspnea despite relative preservation of left ventricular ejection fraction. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are one of the classes of glucose-lowering therapies that have demonstrated multi-system health benefits. The three inhibitors that are used are: empaglifozin, canaglifozin and dapagliflozin. Empaglifozin reduced the risk of pump failure and sudden death, the two most common modes in patients with heart failure. Regardless of their actions on blood glucose, SGLT2 inhibitors exert a wide range of biological effects including actions to inhibit cardiac inflammation and fibrosis, antagonize sodium retention, and improve glomerular function that may ameliorate the pathophysiological disorders of heart failure.
publishDate 2022
dc.date.none.fl_str_mv 2022-05-02
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/29361
10.33448/rsd-v11i6.29361
url https://rsdjournal.org/index.php/rsd/article/view/29361
identifier_str_mv 10.33448/rsd-v11i6.29361
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/29361/25362
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 6; e42411629361
Research, Society and Development; Vol. 11 Núm. 6; e42411629361
Research, Society and Development; v. 11 n. 6; e42411629361
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052711903952896